MLTX MoonLake Immunotherapeutics | $52.62
-3.1% | 9/14/2023 | | Downgrade | | Buy ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 9/14/2023 |
TVTX Travere Therapeutics | $23.47
-6.1% | 5/5/2023 | | Upgrade | | Sell ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Travere Therapeutics (NASDAQ:TVTX) on 5/5/2023 |
IMCR Immunocore | $35.24
-3.6% | 3/24/2023 | | Initiated Coverage | $16.00 | Buy | 00.00% | View details for Bryan, Garnier & Co rating of Immunocore (NASDAQ:IMCR) on 3/24/2023 |
IMTX Immatics | $5.82
-1.7% | 3/24/2023 | | Initiated Coverage | $16.00 | Buy | 00.00% | View details for Bryan, Garnier & Co rating of Immatics (NASDAQ:IMTX) on 3/24/2023 |
ADAP Adaptimmune Therapeutics | $0.06
+10.9% | 3/24/2023 | | Initiated Coverage | $3.60 | Buy | 00.00% | View details for Bryan, Garnier & Co rating of Adaptimmune Therapeutics (NASDAQ:ADAP) on 3/24/2023 |
CRSP CRISPR Therapeutics | $56.26
+0.7% | 3/17/2023 | | Initiated Coverage | $70.00 | Buy | 00.00% | View details for Bryan, Garnier & Co rating of CRISPR Therapeutics (NASDAQ:CRSP) on 3/17/2023 |
CLLS Cellectis | $2.89
-3.0% | 3/17/2023 | | Initiated Coverage | $6.00 | Buy | 00.00% | View details for Bryan, Garnier & Co rating of Cellectis (NASDAQ:CLLS) on 3/17/2023 |
AUTL Autolus Therapeutics | $1.38
-3.5% | 3/17/2023 | | Initiated Coverage | $5.00 | Buy | 00.00% | View details for Bryan, Garnier & Co rating of Autolus Therapeutics (NASDAQ:AUTL) on 3/17/2023 |
MLTX MoonLake Immunotherapeutics | $52.62
-3.1% | 2/2/2023 | | Initiated Coverage | $22.00 | Buy | 00.00% | View details for Bryan, Garnier & Co rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 2/2/2023 |
PHVS Pharvaris | $23.20
-1.3% | 10/5/2022 | | Initiated Coverage | $16.00 | Buy | 00.00% | View details for Bryan, Garnier & Co rating of Pharvaris (NASDAQ:PHVS) on 10/5/2022 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
TVTX Travere Therapeutics | $23.47
-6.1% | 9/21/2022 | | Initiated Coverage | $17.00 | Sell | 00.00% | View details for Bryan, Garnier & Co rating of Travere Therapeutics (NASDAQ:TVTX) on 9/21/2022 |
TAP Molson Coors Beverage | $48.36
-1.6% | 9/1/2022 | | Downgrade | $54.00 | Buy ➝ Sell | 00.00% | View details for Bryan, Garnier & Co rating of Molson Coors Beverage (NYSE:TAP) on 9/1/2022 |
GMAB Genmab A/S | 27.82
-2.8% | 5/13/2022 | | Upgrade | | Sell ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Genmab A/S (NASDAQ:GMAB) on 5/13/2022 |
NVO Novo Nordisk A/S | $54.94
+1.2% | 5/5/2022 | | Upgrade | | Sell ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Novo Nordisk A/S (NYSE:NVO) on 5/5/2022 |
BLDR Builders FirstSource | $142.74
-2.6% | 4/6/2022 | | Downgrade | $71.00 | Buy ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Builders FirstSource (NYSE:BLDR) on 4/6/2022 |
NVS Novartis | $124.12
-2.8% | 12/3/2021 | | Reiterated Rating | $115.00 ➝ $85.00 | Buy ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Novartis (NYSE:NVS) on 12/3/2021 |
AZN AstraZeneca | $79.56
-1.9% | 11/22/2021 | | Downgrade | | Buy | 00.00% | View details for Bryan, Garnier & Co rating of AstraZeneca (NASDAQ:AZN) on 11/22/2021 |
NVO Novo Nordisk A/S | 54.94
+1.2% | 11/3/2021 | | Downgrade | 148.00 | Buy ➝ Sell | 00.00% | View details for Bryan, Garnier & Co rating of Novo Nordisk A/S (NYSE:NVO) on 11/3/2021 |
BNTX BioNTech | $96.74
-7.3% | 10/5/2021 | | Set Price Target | $359.00 | | 00.00% | View details for Bryan, Garnier & Co rating of BioNTech (NASDAQ:BNTX) on 10/5/2021 |
BNTX BioNTech | $96.74
-7.3% | 9/24/2021 | | Set Price Target | $451.00 | | 00.00% | View details for Bryan, Garnier & Co rating of BioNTech (NASDAQ:BNTX) on 9/24/2021 |
VALN Valneva | $8.94
-2.6% | 9/13/2021 | | Downgrade | | Buy ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Valneva (NASDAQ:VALN) on 9/13/2021 |
BNTX BioNTech | $96.74
-7.3% | 8/11/2021 | | Upgrade | | Neutral ➝ Buy | 00.00% | View details for Bryan, Garnier & Co rating of BioNTech (NASDAQ:BNTX) on 8/11/2021 |
MOR MorphoSys | $18.96
| 6/3/2021 | | Downgrade | | Buy ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of MorphoSys (NASDAQ:MOR) on 6/3/2021 |
BNTX BioNTech | $96.74
-7.3% | 5/17/2021 | | Reiterated Rating | $135.00 ➝ $206.00 | Buy ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of BioNTech (NASDAQ:BNTX) on 5/17/2021 |
BNTX BioNTech | $96.74
-7.3% | 5/11/2021 | | Downgrade | $135.00 ➝ $206.00 | Buy ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of BioNTech (NASDAQ:BNTX) on 5/11/2021 |
BUD Anheuser-Busch InBev SA/NV | $58.35
-1.1% | 5/6/2021 | | Upgrade | | Sell ➝ Buy | 00.00% | View details for Bryan, Garnier & Co rating of Anheuser-Busch InBev SA/NV (NYSE:BUD) on 5/6/2021 |
DBVT DBV Technologies | $9.87
-0.8% | 5/3/2021 | | Upgrade | | Sell ➝ Buy | 00.00% | View details for Bryan, Garnier & Co rating of DBV Technologies (NASDAQ:DBVT) on 5/3/2021 |
GNFT GENFIT | $4.20
+0.3% | 2/12/2021 | | Upgrade | | Neutral ➝ Buy | 00.00% | View details for Bryan, Garnier & Co rating of GENFIT (NASDAQ:GNFT) on 2/12/2021 |
STM STMicroelectronics | $25.94
-0.8% | 1/8/2021 | | Upgrade | | Neutral ➝ Buy | 00.00% | View details for Bryan, Garnier & Co rating of STMicroelectronics (NYSE:STM) on 1/8/2021 |
STM STMicroelectronics | $25.94
-0.8% | 12/10/2020 | | Downgrade | | Buy ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of STMicroelectronics (NYSE:STM) on 12/10/2020 |
GMAB Genmab A/S | $27.82
-2.8% | 9/23/2020 | | Downgrade | | Neutral ➝ Sell | 00.00% | View details for Bryan, Garnier & Co rating of Genmab A/S (NASDAQ:GMAB) on 9/23/2020 |
IHG Intercontinental Hotels Group | $121.19
-1.8% | 9/21/2020 | | Downgrade | | Neutral ➝ Sell | 00.00% | View details for Bryan, Garnier & Co rating of Intercontinental Hotels Group (NYSE:IHG) on 9/21/2020 |
IPHA Innate Pharma | $2.00
-2.0% | 9/9/2020 | | Downgrade | | Buy ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Innate Pharma (NASDAQ:IPHA) on 9/9/2020 |
DBVT DBV Technologies | $9.87
-0.8% | 8/4/2020 | | Downgrade | | Neutral ➝ Sell | 00.00% | View details for Bryan, Garnier & Co rating of DBV Technologies (NASDAQ:DBVT) on 8/4/2020 |
BUD Anheuser-Busch InBev SA/NV | $58.35
-1.1% | 7/15/2020 | | Downgrade | | Buy ➝ Sell | 00.00% | View details for Bryan, Garnier & Co rating of Anheuser-Busch InBev SA/NV (NYSE:BUD) on 7/15/2020 |
TAP Molson Coors Beverage | $48.36
-1.6% | 7/15/2020 | | Upgrade | $49.00 | Sell ➝ Buy | 00.00% | View details for Bryan, Garnier & Co rating of Molson Coors Beverage (NYSE:TAP) on 7/15/2020 |
DEO Diageo | $101.77
-1.9% | 7/8/2020 | | Upgrade | | Neutral ➝ Buy | 00.00% | View details for Bryan, Garnier & Co rating of Diageo (NYSE:DEO) on 7/8/2020 |
BNTX BioNTech | $96.74
-7.3% | 7/2/2020 | | Boost Price Target | $50.00 ➝ $62.00 | | 00.00% | View details for Bryan, Garnier & Co rating of BioNTech (NASDAQ:BNTX) on 7/2/2020 |
STM STMicroelectronics | $25.94
-0.8% | 6/29/2020 | | Upgrade | | Neutral ➝ Buy | 00.00% | View details for Bryan, Garnier & Co rating of STMicroelectronics (NYSE:STM) on 6/29/2020 |
GMAB Genmab A/S | $27.82
-2.8% | 6/3/2020 | | Downgrade | | Buy ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Genmab A/S (NASDAQ:GMAB) on 6/3/2020 |
|
CGC Canopy Growth | $1.37
-1.4% | 6/1/2020 | | Downgrade | | Neutral ➝ Sell | 00.00% | View details for Bryan, Garnier & Co rating of Canopy Growth (NASDAQ:CGC) on 6/1/2020 |
GNFT GENFIT | $4.20
+0.3% | 5/13/2020 | | Downgrade | | Buy ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of GENFIT (NASDAQ:GNFT) on 5/13/2020 |
DBVT DBV Technologies | $9.87
-0.8% | 3/18/2020 | | Downgrade | | Buy ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of DBV Technologies (NASDAQ:DBVT) on 3/18/2020 |
BUD Anheuser-Busch InBev SA/NV | $58.35
-1.1% | 2/28/2020 | | Downgrade | | Buy ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Anheuser-Busch InBev SA/NV (NYSE:BUD) on 2/28/2020 |
ACB Aurora Cannabis | $4.87
-1.2% | 2/27/2020 | | Downgrade | | Neutral ➝ Sell | 00.00% | View details for Bryan, Garnier & Co rating of Aurora Cannabis (NASDAQ:ACB) on 2/27/2020 |
ASML ASML | $813.87
+1.2% | 1/14/2020 | | Upgrade | | Neutral ➝ Buy | 00.00% | View details for Bryan, Garnier & Co rating of ASML (NASDAQ:ASML) on 1/14/2020 |
TAP Molson Coors Beverage | $48.36
-1.6% | 8/1/2019 | | Reiterated Rating | $51.00 | Neutral ➝ Sell | 00.00% | View details for Bryan, Garnier & Co rating of Molson Coors Beverage (NYSE:TAP) on 8/1/2019 |
CGC Canopy Growth | $1.37
-1.4% | 7/5/2019 | | Downgrade | | Buy ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Canopy Growth (NASDAQ:CGC) on 7/5/2019 |
MRK Merck & Co., Inc. | $82.87
-2.7% | 1/13/2017 | | Initiated Coverage | | Buy | 00.00% | View details for Bryan, Garnier & Co rating of Merck & Co., Inc. (NYSE:MRK) on 1/13/2017 |
TAP Molson Coors Beverage | $48.36
-1.6% | 7/8/2016 | | Upgrade | | Buy | 00.00% | View details for Bryan, Garnier & Co rating of Molson Coors Beverage (NYSE:TAP) on 7/8/2016 |
GSK GSK | $40.81
-1.6% | 1/27/2016 | | Upgrade | | Neutral ➝ Buy | 00.00% | View details for Bryan, Garnier & Co rating of GSK (NYSE:GSK) on 1/27/2016 |
ASML ASML | $813.87
+1.2% | 1/21/2016 | | Upgrade | | Neutral ➝ Buy | 00.00% | View details for Bryan, Garnier & Co rating of ASML (NASDAQ:ASML) on 1/21/2016 |
TAP Molson Coors Beverage | $48.36
-1.6% | 11/17/2015 | | Initiated Coverage | $101.00 | Buy | 00.00% | View details for Bryan, Garnier & Co rating of Molson Coors Beverage (NYSE:TAP) on 11/17/2015 |
SNY Sanofi | $47.03
-1.3% | 11/9/2015 | | Reiterated Rating | | Buy ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Sanofi (NASDAQ:SNY) on 11/9/2015 |
AZN AstraZeneca | $79.56
-1.9% | 9/18/2015 | | Upgrade | | Neutral ➝ Buy | 00.00% | View details for Bryan, Garnier & Co rating of AstraZeneca (NASDAQ:AZN) on 9/18/2015 |
NVS Novartis | $124.12
-2.8% | 6/22/2015 | | Upgrade | | Neutral ➝ Buy | 00.00% | View details for Bryan, Garnier & Co rating of Novartis (NYSE:NVS) on 6/22/2015 |
BUD Anheuser-Busch InBev SA/NV | $58.35
-1.1% | 5/5/2015 | | Initiated Coverage | | Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Anheuser-Busch InBev SA/NV (NYSE:BUD) on 5/5/2015 |
AEG Aegon | $7.75
+1.0% | 4/15/2015 | | Upgrade | | Neutral ➝ Buy | 00.00% | View details for Bryan, Garnier & Co rating of Aegon (NYSE:AEG) on 4/15/2015 |
NVO Novo Nordisk A/S | $54.94
+1.2% | 3/26/2015 | | Downgrade | | Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Novo Nordisk A/S (NYSE:NVO) on 3/26/2015 |
SAP SAP | $257.10
-0.4% | 1/20/2015 | | Downgrade | | Buy ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of SAP (NYSE:SAP) on 1/20/2015 |
DEO Diageo | $101.77
-1.9% | 12/4/2014 | | Initiated Coverage | | Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Diageo (NYSE:DEO) on 12/4/2014 |
CRH CRH | $113.44
-0.9% | 9/12/2014 | | Upgrade | | Sell ➝ Buy | 00.00% | View details for Bryan, Garnier & Co rating of CRH (NYSE:CRH) on 9/12/2014 |
AZN AstraZeneca | $79.56
-1.9% | 12/20/2013 | | Downgrade | | Buy ➝ Neutral | 00.00% | View details for Bryan, Garnier & Co rating of AstraZeneca (NASDAQ:AZN) on 12/20/2013 |
MRK Merck & Co., Inc. | €82.87
-2.7% | 4/16/2013 | | Reiterated Rating | €100.00 | Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Merck & Co., Inc. (NYSE:MRK) on 4/16/2013 |
MRK Merck & Co., Inc. | €82.87
-2.7% | 12/19/2012 | | Reiterated Rating | €96.00 | Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Merck & Co., Inc. (NYSE:MRK) on 12/19/2012 |
MRK Merck & Co., Inc. | €82.87
-2.7% | 10/12/2012 | | Downgrade | €91.79 | Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Merck & Co., Inc. (NYSE:MRK) on 10/12/2012 |
BEAM Beam Therapeutics | $20.60
-4.4% | 9/20/2012 | | Reiterated Rating | | Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Beam Therapeutics (NASDAQ:BEAM) on 9/20/2012 |
BEAM Beam Therapeutics | $20.60
-4.4% | 9/12/2012 | | Reiterated Rating | | Neutral | 00.00% | View details for Bryan, Garnier & Co rating of Beam Therapeutics (NASDAQ:BEAM) on 9/12/2012 |
